OCT 21·SEC EDGARLow
Ziegler Christoph Samuel purchased $33K of VRXA
Ziegler Christoph Samuel purchased 30,000 shares of Veraxa Biotech AG - Post de-SPAC (VRXA) at $1.09 on 2026-10-20.
StockNASDAQ · US · USDHealthcare · Biotechnology
$VRXA
Veraxa Biotech AG - Post de-SPAC
Veraxa is an oncology-focused biotechnology and clinical drug development company based in Zurich, Switzerland. Its pipeline includes VX-A901, an antibody that has completed a Phase I clinical trial for the treatment of acute myeloid leukemia. Veraxa also has the BiTAC-TCE platform, derived from the in-licensed Hemibody platform. Veraxa’s technologies include Hitmaster and microfluidics-based antibody screening, genetic code expansion, and click chemistry for antibody drug conjugation. Its wholly owned subsidiary, VERAXA Biotech GmbH, conducts all of its research and development activities in Heidelberg, Germany. Veraxa has raised capital to support the advancement of its technologies and programs.
Price · $VRXAvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $VRXA in the last 7 days.
Insider · 30dAll trades →
- Buys
- $33K 1 txs
- Sells
- — 0 txs
Ziegler Christoph Samuel1× · $33K
10b5-1 share of filings0%
Top stories · $VRXAMore →
OCT 13·finanznachrichten.de
Veraxa Biotech AG: VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC-ADC Technology at World ADC Congress
VERAXA Biotech AG (NASDAQ: VRXA) presented in vivo proof-of-concept data for its BiTAC-ADC technology at the World ADC Congress. The data showed significant tumor regression in a breast cancer model with a single dose, while maintaining safety. The company highlights the potential for safer cancer treatments with comparable efficacy to conventional ADCs.
OCT 7·rttnews.com
Biotech Stocks In Focus - SXTC +536% On Sharp Move; VRXA, AVBP, SPRC On Key Developments
China SXT Pharmaceuticals (SXTC) shares surged 536% post-share consolidation, with recent financing plans. VERAXA Biotech (VRXA) rose 15% after adopting FDA-aligned methodologies. ArriVent BioPharma (AVBP) gained 12% despite a missed Phase 3 trial endpoint. SciSparc (SPRC) climbed 8% on quantum analysis advancements.
VRXA sentiment & insider activity
Recent VRXA coverage spans financial news, insider activity and technology.
In the last 30 days, VRXA insiders filed 1 SEC Form 4 transaction — 1 purchase ($33K) and no sales. The most active reporter was Ziegler Christoph Samuel with 1 filing.
What's driving VRXA
Small insider purchase may signal confidence but size is modest.
Positive preclinical data could boost investor confidence and lift the stock.
Adoption of NAMs may lower development costs and speed timelines, supporting upside.
The announcement may boost investor confidence and lift the stock on expectations of faster, cheaper clinical progress.
The strategy may lower development costs and timelines, offering a modest upside.
AlphAI scores every news story that mentions VRXA with an AI model for sentiment and relevance, and aggregates insider trades from Veraxa Biotech AG - Post de-SPAC's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $VRXA
Score
Ziegler Christoph Samuel purchased $33K of VRXA
Ziegler Christoph Samuel purchased 30,000 shares of Veraxa Biotech AG - Post de-SPAC (VRXA) at $1.09 on 2026-10-20.
1 min readVeraxa Biotech AG: VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC-ADC Technology at World ADC Congress
VERAXA Biotech AG (NASDAQ: VRXA) presented in vivo proof-of-concept data for its BiTAC-ADC technology at the World ADC Congress. The data showed significant tumor regression in a breast cancer model with a single dose, while maintaining safety. The company highlights the potential for safer cancer treatments with comparable efficacy to conventional ADCs.
2 min readBiotech Stocks In Focus - SXTC +536% On Sharp Move; VRXA, AVBP, SPRC On Key Developments
China SXT Pharmaceuticals (SXTC) shares surged 536% post-share consolidation, with recent financing plans. VERAXA Biotech (VRXA) rose 15% after adopting FDA-aligned methodologies. ArriVent BioPharma (AVBP) gained 12% despite a missed Phase 3 trial endpoint. SciSparc (SPRC) climbed 8% on quantum analysis advancements.
3 min readVeraxa Biotech stock gains on FDA-aligned testing strategy
Veraxa Biotech AG (VRXA) shares rose 3.7% premarket after announcing an FDA-aligned strategy to reduce animal testing in preclinical programs. The approach uses New Approach Methodologies, aiming to cut costs and timelines. The company presented data on its BiTAC-TCE program at AACR 2026, showing targeted cancer cell killing with minimal activity against non-expressed targets.
2 min readVeraxa Biotech AG: VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
VERAXA Biotech AG (VRXA) announced its adoption of FDA-aligned New Approach Methodologies (NAMs) in its R&D strategy, aiming to accelerate its BiTAC oncology pipeline and reduce animal testing. The company presented initial data at the AACR Annual Meeting 2026, showing promising results for its BiTAC-TCE program. VERAXA's NAMs include cell-based assays, organ-on-chip systems, and computational modeling, which the company believes will reduce development costs and timelines.
2 min readHosseinion Warren purchased $10K of VRXA
Hosseinion Warren purchased 6,024 shares of Veraxa Biotech AG (VRXA) at $1.67 on 2026-09-10.
1 min read
VERAXA Biotech (NASDAQ: VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress
VERAXA Biotech (VRXA) is advancing its oncology pipeline and forming industrial partnerships after its Nasdaq debut in June 2026. Xlife Sciences (XLS) reported progress in its portfolio, including VERAXA, and plans to continue supporting its commercialization and partnerships. Xlife's portfolio includes 416 patents, with 216 granted.
1 min readVERAXA Biotech (NASDAQ: VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase
VERAXA Biotech (VRXA) is advancing its oncology pipeline using its BiTAC platform, which targets cancer cells with a dual-component approach. The company went public on NASDAQ in June 2026 via a merger with Voyager Acquisition Corp. and has since reported early preclinical data for its BiTAC-TCE and BiTAC-ADC approaches. Recent executive appointments include a new CFO and chief scientific officer.
1 min read
VERAXA Biotech (VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline
VERAXA Biotech (VRXA) has appointed Raju Willener as CFO, bringing 30 years of finance experience. The company is advancing its BiTAC oncology pipeline, with early data showing promise. Willener previously worked at Exentis Group AG.
1 min read
VERAXA Biotech Designates Raju Willener as CFO
Veraxa Biotech AG (VRXA) named Raju Willener as its new Chief Financial Officer. Willener brings over 30 years of financial leadership experience in biopharmaceuticals. CEO Christoph Antz stated Willener's expertise will support capital strategy and shareholder value creation.
1 min read